Results 31 to 40 of about 5,463 (146)

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, EarlyView.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P. Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes’ army

Future Science OA, 2019
Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.
Ricardo García-Muñoz, María-Josefa Nájera, Jesús Feliu, Judith Antón-Remírez, Enrique Ramalle-Gómara, Raquel Marín-Gorricho, Raisa Peralta, Elena Gutiérrez-Gamarra, Jessica Nuñez-Rodriguez, Ricardo Zafra-Morales, Lorea Aguinaga, María-Jose Nebot-Villacampa, Prisma-Monserrat Hernandez-Pérez, Giovanna Farfán-Quiroga, Carlos Panizo, Elena Domínguez-Garrido   +15 more
doaj   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

Therapeutics and Clinical Risk Management, 2015
Arpita Shah Department of Pharmacy, Georgia Regents University Medical Center, Augusta, GA, USA Abstract: Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent
Shah A
doaj  

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction Overweight and obesity are increasing rapidly in most countries. Underweight body mass index (BMI), though much less common, is also associated with adverse health outcomes. There is poor understanding of the implications of BMI in lymphoma patients.
Serif Sungur, Yao Yao, Cameron Wellard, Eliza Chung, Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Tasneem Rizvi, Eliza A. Hawkes, Zoe K. McQuilten, Erica M. Wood, Nada Hamad, Tasman Armytage, Anna M. Johnston   +14 more
wiley   +1 more source

Obinutuzumab-induced acute thrombocytopenia: a case report and literature review

Frontiers in Oncology
BackgroundObinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphomas. Thrombocytopenia typically occurs 1 to 2 weeks after administration.
Xuelin Dou, Kongyang Li, Kongyang Li, Jin Lu   +3 more
doaj   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review

Frontiers in Pharmacology
BackgroundObinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).
Chao Wang, Yunzhuo Dong, Peng Men, Ruixia Zhang, Ying Xiao, Yishan Bu, Yinpeng Qin, Xinran Zhang, Qianqian Dou, Yiheng Yang, Huier Gao, Yi Zhang   +11 more
doaj   +1 more source